Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02989025 · ClinicalTrials.gov registry record · Phase 2
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
A Phase 2 study of Pregnancy and Preeclampsia (PE), sponsored by University of Mississippi Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT02989025 is a Phase 2 study of Pregnancy and Preeclampsia (PE) that is actively recruiting participants, run by University of Mississippi Medical Center. The registered enrollment target is 60 participants, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02989025, a Phase 2 study of Pregnancy and Preeclampsia (PE), is actively recruiting participants, sponsored by University of Mississippi Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
Conditions Studied
Interventions
- DRUG 17 OHPC
Study Locations (1)
Mississippi
- Winfred L. Wiser Hospital - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02989025
The ClinicalTrials.gov registry entry for NCT02989025 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (93% lower). The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which 17 OHPC is the first listed.
NCT02989025 reports 1 study location spanning 1 distinct geographic area - top geographies include Mississippi.
Frequently Asked Questions
What is clinical trial NCT02989025 about?
NCT02989025 is a clinical study titled "Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia". The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
What is the current status of trial NCT02989025?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-05-22. Estimated completion is 2027-01-31.
What conditions does trial NCT02989025 study?
This clinical trial studies the following conditions: Pregnancy, Preeclampsia (PE).
What interventions are being tested in trial NCT02989025?
The interventions under investigation include: 17 OHPC (DRUG).
Who is sponsoring clinical trial NCT02989025?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02989025 being conducted?
This trial has 1 study location across Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Pharmacology of 17-OHPC in Pregnancy
COMPLETED · Phase 2
-
Healthy4Baby: Preventing Postpartum Weight Retention Among Low-Income, Black Women
COMPLETED · Phase 2
-
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
COMPLETED · Phase 2
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.